By Matt Grossman


Roche Holding AG has gained approval from the U.S. Food and Drug Administration for a diagnostic test used to determine whether patients with endometrial cancer will benefit from a particular treatment.

The test, called Ventana MMR RxDx, can help physicians decide whether an endometrial cancer patient should be treated with Jemperli, an anti-PD1 immunotherapy from GlaxoSmithKline PLC.

The test uses a comprehensive panel of DNA mismatch repair biomarkers tested by immunohistochemistry, Roche said.


Write to Matt Grossman at


(END) Dow Jones Newswires

April 23, 2021 06:32 ET (10:32 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.